Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Verana Health aims to go deep with its real-world data network

By Brian Buntz | January 25, 2022

Verana HealthThe task of extracting health insights from electronic health records (EHRs) has taken longer to materialize than some pundits projected a decade or so ago. But the situation is quickly changing with continued advances in data science, said Sujay Jadhav, CEO of Verana Health (San Francisco), which has created a real-world data network in partnership with 20,000 healthcare providers.

Pharma and biotech companies have used the company’s data to inform study design and site selection and to finesse clinical trial execution.

The company recently attracted $150 million in Series E funding round led by Johnson & Johnson Innovation (JJDC) and Novo Growth.

“To a certain extent, the technologies we are leveraging to extract, normalize and curate data to provide insights have been around for more than a decade,” Jadhav said.

Progress has ramped up as security technologies have evolved to offer more robust protection and deidentification of patient privacy.

Sujay Jadhav

Sujay Jadhav

Another hurdle is the challenge of working with unstructured data. “Broadly speaking, the industry has done a really good job of accessing structured data such as claims data in an aggregated fashion and providing insights around that,” Jadhav said.

A growing number of companies are now focusing on parsing unstructured EHR data. “Right now, we’re focused on going through the process of curating that [unstructured data] and deidentifying it to provide the next level of value of insights,” Jadhav said.

Focusing on EHR data can provide more timely insights than other sources such as claims data.

Historical sources such as claims data can take months of processing time before they are available. “But with EHR data, you can get close to real-time,” Jadhav said.

Such EHR data can also provide insights into the overall drug lifecycle.

The pandemic has fueled interest in accelerating development timelines, increasing demand for techniques such as natural language processing (NLP) and decentralized clinical trials.

Another factor that has held back the use of data science in healthcare in the past is a lack of understanding of the nuances inherent in particular medical specialties.

To address that challenge, Verana Health has chosen to constrain its focus to three therapeutic areas, including ophthalmology, neurology and urology for the time being. The company has partnerships with the American Academy of Ophthalmology, the American Urological Association and the American Academy of Neurology. The heads of those three societies have positions on Verana Health’s board.

Such partnerships ensure that the company is “doing what we need to do in furthering medical research in those therapeutic areas,” Jadhav said, while also providing feedback for the company’s overall business model, “which we can scale to other therapeutic areas as well,” Jadhav concluded.

 


Filed Under: clinical trials, Data science, Drug Discovery
Tagged With: clinical trials, EHR, electronic health records, real-world data, real-world evidence, RWD, RWE, Verana Health
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Abstract neural network
Inside IQVIA’s quest to build a multi-agent AI ‘dream team’ to transform clinical trials
Xaira and Verily co-founder ponders low-hanging fruit and blue-sky potential in FDA’s genAI rollout
Capgemini’s life-sciences lead says ROI and data security, not algorithms, will decide pharma’s AI future
Portrait of happy smiling mature middle aged professional business woman investor manager executive or lawyer attorney looking at camera at workplace working on laptop computer in office.
As FDA pushes agency-wide generative AI, pharma experience show similar tools can cut clinical study-report drafting time by 30% or more
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE